Icosavax - Ownership and Business Overview

Life ScienceCompany

Icosavax Ownership

Who owns Icosavax?

Icosavax is owned by AstraZeneca. It was acquired on December 12, 2023.

Was Icosavax formerly PE-backed?

Yes. Icosavax was formerly owned by 1 private investor.

Icosavax Business Overview

Where is Icosavax headquartered?

Icosavax is headquartered in Seattle, Washington.

What sector is Icosavax in?

Icosavax is a life science company.

When was Icosavax founded?

Icosavax was founded in 2017.

Life Science M&A Summary in 2023

Out of 60 sectors in the Mergr database, life science ranked 9 in number of deals in 2023. The largest life science acquisition in 2023 was Seagen - which was acquired by Pfizer for $43.0B.

Subscribe to Mergr to view all 212 acquisitions of life science companies in 2023, including 28 acquisitions by private equity firms, and 184 by strategics.

Icosavax

Icosavax, Inc.

1930 Boren Ave, Suite 1000,
Seattle, Washington 98101
United States,
(206) 737-0085
www.icosavax.com

Icosavax is a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Icosavax was founded in 2017 and is based in Seattle, Washington.


 Subscribe to unlock this and 215,016
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.

We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore a company's M&A activity, ownership history, and connections - organized to help you uncover opportunities and make informed decisions.

With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.7K Private Equity Firms
  • 208K M&A Transactions
  • 210K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

What next?

Get Full Access

Full access to Mergr's investor, acquirer, and transaction data starts here.

Related Lists for Icosavax

Life Science Companies